IQARUS INTERNATIONAL LIMITEDActive
Key figures
Like most small UK companies, IQARUS INTERNATIONAL LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Balance sheet structure
Filed accounts2021/22–2024/25
| 2021/22 | 2022/23 | 2023/24 | 2024/25 | |
|---|---|---|---|---|
| Turnover | 31,890,761 | — | — | — |
| Cash at bank and in hand | 983,474 | — | — | — |
| Total assets | 39,300,668 | — | — | — |
| Total liabilities | 41,926,202 | — | — | — |
| Net assets / total equity | 2,625,534 | -1,597,231 | -1,945,757 | -6,553,446 |
| Average number of employees | 12 | 11 | 15 | 0 |
| Average pay (per year) | — | 97,434 | 81,418 | — |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025The company’s principal activities are the development and deployment of healthcare solutions globally.
As described in the company's latest filed accounts.
Summary: IQARUS INTERNATIONAL LIMITED
Company
IQARUS INTERNATIONAL LIMITED is a private limited company registered with Companies House under company number 05080465. It was incorporated on 22 Mar 2004. Its status is active. The registered office is in London (W4). Its nature of business (SIC 2007) is retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) n.e.c. (47749), other education n.e.c. (85590), specialists medical practice activities (86220), other human health activities (86900).
Accounts
The latest accounts in the database are for 2024/25 (period ending 30 Jun 2025); the company files full accounts. Net assets were −£6,553,446, down 236.8% on the previous year. The company had an average of 0 employees. Figures are available for 4 financial years (2021/22–2024/25).
Control and charges
2 persons with significant control are registered.
Filing deadlines
The next accounts are due by 31 Mar 2027. The next confirmation statement is due by 20 Jun 2027.